This program is studying MAT2501, an oral version of the drug amikacin. Amikacin is an antibiotic that targets nontuberculous mycobacteria (NTM) infections in people with cystic fibrosis. An oral formulation of the drug may reduce the risk of known amikacin side effects such as hearing loss and kidney problems. An oral version would also make it easier for someone with an NTM infection to take the drug from home.
Laboratory studies of this formulation are underway.
This program is sponsored by Matinas BioPharma and partially funded by the Cystic Fibrosis Foundation.
Contact us about Matinas Biopharma >